Navigation Links
Cequent Names Ted Hibben Chief Business Officer
Date:1/12/2009

CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Ted Hibben has joined the company as chief business officer. Mr. Hibben comes to Cequent from Coley Pharmaceutical Group, where he was most recently vice president of business development and alliance management and played a key role in the company's $233 million acquisition by Pfizer in 2008. Coley was a publicly traded biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, asthma, infectious diseases, and autoimmune diseases.

"Strategic partners have been key to Cequent's success to date and will become even more important as we continue to move our tkRNAi technology from the laboratory into clinical development against multiple diseases. Ted brings to Cequent a wealth of experience orchestrating a full range of strategic collaborations with leading pharmaceutical and biotech companies - from drug discovery, research, and clinical-development partnerships to licensing agreements," said Cequent President and CEO, Peter Parker. "Beyond his role in the Pfizer acquisition, Ted's recent track record includes closing nearly a dozen alliances totaling $750 million of itemized pre-commercial development milestones with companies like Novartis, GSK, and Merck."

Regarding Mr. Hibben's role at Cequent, Mr. Parker said, "Ted will focus on external partnering activities in three major areas. On our inflammatory bowel disease (IBD) program, he will look for partner(s) to further develop one or more of the 11 targets we are working on for Crohn's disease and ulcerative colitis; he will also seek to partner our CEQ508 candidate for FAP, slated for a Phase I clinical trial in 2009. FAP (familial adenomatous polyposis) is an inherited precursor to
'/>"/>

SOURCE Cequent Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
2. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
3. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
4. Clarus Ventures Names Two New Partners
5. Xceleron Names Michael Butler as President & CEO
6. Genome Technology Names 2008 Tomorrows PIs
7. Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations
8. USP Names Matthew Heyman Vice President of External Affairs and Strategic Integration
9. LCA-Vision Names Michael J. Celebrezze CFO
10. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
11. Great Basin Scientific, Inc. Names Laurence Rea as Vice President of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 (PRWEB) June 18, 2013 ... and attendance system in North America, has introduced ... employee data and payroll records between ExakTime’s software ... automates ExakTime software setup and keeps employee ... employee data from a business’ current payroll software, ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Nasseo, Inc. ... Innovation Challenge Winner out of hundreds of applicants by ... spring Arizona Innovation Challenge . The Arizona Innovation ... for a technology commercialization challenge, granting a financial award ... promising technology ventures. Nasseo’s state of the art dental ...
(Date:6/18/2013)... ALBANY, N.Y. , June 18, 2013 /PRNewswire/ ... that its Burlington, Mass. , ... U.S. Drug Enforcement Administration (DEA) registration to handle ... represents the DEA,s acknowledgement of Burlington,s ... inventory control and documentation. (Logo: ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing ) has announced the addition of ... Markets and Companies " to their offering. ... This report briefly reviews basics of human ... their applications. Current large and small sequencers ...
Breaking Biology Technology:ExakTime Introduces AccountLinx Plus 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... in Total Proceeds Retire Safeguard Mezzanine Debt Facility; Support ... Clarient , Inc. (Nasdaq: CLRT ), ... for pathologists, oncologists and the pharmaceutical industry, announced today ... private placement of convertible preferred stock with ...
... -- China Dasheng,Biotechnology Company ("China Dasheng" or "the Company") ... organic bacteria based additives,for crops and livestock feeds in ... of fiscal year 2009, which ended March 31, 2009. ... (all figures in US$) included:, -- ...
... -- Rodobo International,Inc. (OTC Bulletin Board: RDBO), one of ... for the second quarter and,first six months ended March ... financial highlights include: , Revenue ... $6.3 million, an,increase of 19% compared to Q2 2008. ...
Cached Biology Technology:Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 2Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 3Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 4Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 5Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 6China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results 2China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results 3China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results 4China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results 5China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results 6China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results 7China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results 8Rodobo International, Inc. Reports Q2 and First Half of 2009 2Rodobo International, Inc. Reports Q2 and First Half of 2009 3Rodobo International, Inc. Reports Q2 and First Half of 2009 4Rodobo International, Inc. Reports Q2 and First Half of 2009 5Rodobo International, Inc. Reports Q2 and First Half of 2009 6Rodobo International, Inc. Reports Q2 and First Half of 2009 7Rodobo International, Inc. Reports Q2 and First Half of 2009 8
(Date:6/18/2013)... engineer has been awarded a $394,300 grant from ... quality and flow in the new facilities of ... UT Arlington associate professor of civil engineering, will ... monochloramine to the water in an effort to ... and pipelines. Adding monochloramine is widely practiced throughout ...
(Date:6/18/2013)... a very large "dead zone" in the Gulf of ... the Chesapeake Bay this year, based on several NOAA-supported ... Michigan, Louisiana State University, and the Louisiana Universities ... Mexico hypoxic "dead" zone will be between 7,286 and ... ten largest recorded. That would range from an area ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... of the central nervous system (CNS) in animal evolution ... evolved from the same ancestor, but their CNSs are ... their lineages had split during evolution. Researchers from the ... that the vertebrate nervous system is probably much older ...
... group of organisms that has never had sex in ... to evolve into distinct species, says new research published ... necessary for organisms to diversify and provides scientists with ... place. , The research, published in PLoS Biology, ...
... cancer is a metaphorical example of the perfect invasion by ... on a deserted island in the Galapagos Archipelago, the first ... mutations through many generations to establish itself as an invader ... there, like any newly stabilized species in different ecological niches, ...
Cached Biology News:The origin of the brain lies in a worm 2No sex for 40 million years? No problem 2New bird, bat species revealed by extensive DNA barcode studies 2
The HQ505, 20 OptiGreen filter for the Molecular Imager FX is a band pass filter used for detection of Cy2 and FITC with 532 nm excitation....
The filter 530DF28 for the Molecular Imager FX is a band pass filter for ECL Plus, AttoPhos, SYBR Green, Alexa Fluor 488, FITC, Cy2, and Pro-Q Emerald dyes....
... Fluorescein In Situ Apoptosis Detection Kit ... the indirect TUNEL method, utilizing an ... a Fluorescein reporter molecule. It provides ... Results are analyzed using either flow ...
... 3000 system, 220-240 V, is used for nucleic ... vertical slab gel format. The system includes the ... of separating nucleic acids with single base-pair resolution ... (IPC and bonded inner glass plate, outer glass ...
Biology Products: